期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 5, 页码 2934-2937出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.05163-14
关键词
-
资金
- Intramural Research Program of the NIAID
- NIH
Dihydroartemisinin-piperaquine is the current frontline artemisinin combination therapy (ACT) for Plasmodium falciparum malaria in Cambodia but is now failing in several western provinces. To investigate artesunate plus mefloquine (AS + MQ) as a replacement ACT, we measured the prevalence of multiple pfmdr1 copies-a molecular marker for MQ resistance-in 844 P. falciparum clinical isolates collected in 2008 to 2013. The pfmdr1 copy number is decreasing in Western Cambodia, suggesting that P. falciparum is regaining in vitro susceptibility to MQ.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据